Optical Coherence Tomography Angiography to Distinguish Changes of Choroidal Neovascularization after Anti-VEGF Therapy: Monthly Loading Dose versus Pro Re Nata Regimen

作者: Alexandra Miere , Hassiba Oubraham , Francesca Amoroso , Pauline Butori , Polina Astroz

DOI: 10.1155/2018/3751702

关键词: Macular degenerationOphthalmologyPro re nataLesionOptical coherence tomography angiographyAnti vegfMedicineChoroidal neovascularizationLoading doseRegimen

摘要: Purpose. To compare the qualitative and quantitative choroidal neovascularization (CNV) changes after antivascular endothelial growth factor (anti-VEGF) therapy in treatment-naive treated eyes with age-related macular degeneration (AMD) using optical coherence tomography angiography (OCTA). Methods. Consecutive patients neovascular AMD underwent multimodal imaging, including OCTA (AngioPlex, CIRRUS HD-OCT model 5000; Carl Zeiss Meditec, Inc., Dublin, OH) at baseline three monthly follow-up visits. Treatment-naive undergoing anti-VEGF loading phase were included group A, while B. Qualitative analyses performed on outer retina to choriocapillaris (ORCC) slab. CNV size was measured a free image analysis software (ImageJ, open-source imaging processing software, 2.0.0). Results. Twenty-five of 25 enrolled our study (mean age 78.32 ± 6.8 years): 13 A 12 While revealed no significant differences from two groups, showed decrease lesion area ( ); B, change observed during ). Conclusion. secondary respond differently therapy. This should be taken into account when for or planning therapeutic strategies.

参考文章(30)
Daniel F Martin, Maureen G Maguire, Stuart L Fine, Gui-shuang Ying, Glenn J Jaffe, Juan E Grunwald, Cynthia Toth, Maryann Redford, Frederick L Ferris 3rd, Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, None, Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. ,vol. 119, pp. 1388- 1398 ,(2012) , 10.1016/J.OPHTHA.2012.03.053
Gabriel Coscas, Marco Lupidi, Florence Coscas, Catherine Français, Carlo Cagini, Eric H. Souied, Optical coherence tomography angiography during follow-up: qualitative and quantitative analysis of mixed type I and II choroidal neovascularization after vascular endothelial growth factor trap therapy. Ophthalmic Research. ,vol. 54, pp. 57- 63 ,(2015) , 10.1159/000433547
Yali Jia, Ou Tan, Jason Tokayer, Benjamin Potsaid, Yimin Wang, Jonathan J. Liu, Martin F. Kraus, Hrebesh Subhash, James G. Fujimoto, Joachim Hornegger, David Huang, Split-spectrum amplitude-decorrelation angiography with optical coherence tomography Optics Express. ,vol. 20, pp. 4710- 4725 ,(2012) , 10.1364/OE.20.004710
Caio V. Regatieri, Lauren Branchini, Jay S. Duker, The Role of Spectral-Domain OCT in the Diagnosis and Management of Neovascular Age-Related Macular Degeneration Ophthalmic Surgery Lasers & Imaging. ,vol. 42, ,(2011) , 10.3928/15428877-20110627-05
Brandon G. Busbee, Allen C. Ho, David M. Brown, Jeffrey S. Heier, Ivan J. Suñer, Zhengrong Li, Roman G. Rubio, Phillip Lai, Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. ,vol. 120, pp. 1046- 1056 ,(2013) , 10.1016/J.OPHTHA.2012.10.014
grupo estudio VIEW2 HHO Dominguez, None, Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. ,vol. 119, pp. 2537- 2548 ,(2012) , 10.1016/J.OPHTHA.2012.09.006
Eric Moult, WooJhon Choi, Nadia K. Waheed, Mehreen Adhi, ByungKun Lee, Chen D. Lu, Vijaysekhar Jayaraman, Benjamin Potsaid, Philip J. Rosenfeld, Jay S. Duker, James G. Fujimoto, Ultrahigh-speed swept-source OCT angiography in exudative AMD. Ophthalmic Surgery and Lasers. ,vol. 45, pp. 496- 505 ,(2014) , 10.3928/23258160-20141118-03
Anne E. Fung, Geeta A. Lalwani, Philip J. Rosenfeld, Sander R. Dubovy, Stephan Michels, William J. Feuer, Carmen A. Puliafito, Janet L. Davis, Harry W. Flynn, Maria Esquiabro, An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. American Journal of Ophthalmology. ,vol. 143, pp. 566- 583 ,(2007) , 10.1016/J.AJO.2007.01.028